The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy

1. SEO K, KITAZAWA T, YOSHINO Y, et al. Characteristics of serum endocan levels in infection. PLoS One. 2015; 10(4):e0123358.10.1371/journal.pone.0123358440433525894539Search in Google Scholar

2. COX LA, VAN EIJK LT, RAMAKERS BP, et al. Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock. 2015; 43(4):322-326.10.1097/SHK.000000000000032025565643Search in Google Scholar

3. SCHERPEREEL A, DEPONTIEU F, GRIGORIU B, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med.2006; 34(2):532-537.10.1097/01.CCM.0000198525.82124.74Search in Google Scholar

4. PALUD A, PARMENTIER-DECRUCQ E, PASTRE J, et al. Evaluation of endothelial biomarkers as predictors of organ failures in septic shock patients. Cytokine. 2015; 73(2):213-218.10.1016/j.cyto.2015.02.01325794660Search in Google Scholar

5. YANG J, YANG Q, YU S, et al. Endocan: A new marker for cancer and a target for cancer therapy. Biomed Rep. 2015; 3(3):279-283.10.3892/br.2015.438446722526137222Search in Google Scholar

6. BALTA S, MIKHAILIDIS DP, DEMIRKOL S, et al. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosclerosis.2015; 243(1):339-343.10.1016/j.atherosclerosis.2015.09.03026448266Search in Google Scholar

7. HUANG GW, TAO YM, DING X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci. 2009; 54(2):389-394.10.1007/s10620-008-0346-318592377Search in Google Scholar

8. NAULT JC, GUYOT E, LAGUILLIER C, et al. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev.2013; 22(8):1343-1352.10.1158/1055-9965.EPI-13-017923780836Search in Google Scholar

9. OZAKI K, TOSHIKUNI N, GEORGE J, et al. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer. 2014; 5(3):221-230.10.7150/jca.7691396307924665346Search in Google Scholar

10. TOK D, EKIZ F, BASAR O, et al. Serum endocan levels in patients with chronic liver disease. Int J Clin Exp Med. 2014; 7(7):1802-1807.Search in Google Scholar

11. TOSHIKUNI N, OZAKI K, GEORGE J, et al. Serum endocan as a survival predictor for patients with liver cirrhosis. Can J Gastroenterol Hepatol. 2015; 29(8):427-430.10.1155/2015/153805469960926669300Search in Google Scholar

12. MØLLER S, HENRIKSEN J.H. Cardiovascular complications of cirrhosis. Gut. 2008; 57:268–278.10.1136/gut.2006.112177Search in Google Scholar

13. GOLDBERG, DS, FALLON MB. The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease. Clin Gastroenterol Hepatol. 2015; 13(12):2118-2127.10.1016/j.cgh.2015.04.024Search in Google Scholar

14. LOPEZ-TALAVERA JC, CADELINA G, OLCHOWSKI J, et al. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 2016; 23:1616–1621.10.1002/hep.510230644Search in Google Scholar

15. KUDDUS RH, NALESNIK MA, SUBBOTIN VM, et al. Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes--an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis. J Hepatol. 2000; 33(5):725-732.10.1016/S0168-8278(00)80302-5Search in Google Scholar

16. BALDASSARRE M, GIANNONE FA, NAPOLI L, et al. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives. Liver Int. 2013; 33:1298–1308.10.1111/liv.1226323890208Search in Google Scholar

17. BUSK TM, BENDTSEN F, NIELSEN HJ, et al. TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. Scand J Gastroenterol.2014; 49(9):1103-1110.10.3109/00365521.2014.93491025048331Search in Google Scholar

18. MORTENSEN C, JENSEN JS, HOBOLTH L, et al. Association of markers of bacterial translocation with immune activation in decompensated cirrhosis. Eur J Gastroenterol Hepatol.2016; 26(12):1360-6.10.1097/MEG.000000000000021725357217Search in Google Scholar

19. WIEST R, LAWSON M, GEUKING M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014; 60(1):197-209.10.1016/j.jhep.2013.07.04423993913Search in Google Scholar

20. GASKARI SA, LIU H, D’MELLO C, et al. Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoids. J Hepatol.2015; 62(6):1272-7.10.1016/j.jhep.2015.01.021504525925640062Search in Google Scholar

21. VOIOSU AM, DAHA IC, VOIOSU TA, et al. Prevalence and impact on survival of hepatopulmonary syndrome and cirrhotic cardiomyopathy in a cohort of cirrhotic patients. Liver Int. 2015; 35(12):2547-2555.10.1111/liv.1286625974637Search in Google Scholar

22. NAGUEH SF, APPLETON CP, GILLEBERT TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009; 22:107–133.10.1016/j.echo.2008.11.02319187853Search in Google Scholar

23. VOIOSU T, BALANESCU P, BENGUS A, et al. Serum endocan levels are increased in patients with inflammatory bowel disease. Clin Lab.2014; 60(3):505-510.10.7754/Clin.Lab.2013.13033324697130Search in Google Scholar

24. BĂLĂNESCU P, LADARU A, BĂLĂNESCU E, et al. Endocan, Novel Potential Biomarker for Systemic Sclerosis: Results of a Pilot Study. J Clin Lab Anal. 2016; 30(5):368-373.10.1002/jcla.21864680701926331941Search in Google Scholar

25. DALLIO M, MASARONE M, CAPRIO GG, et al. Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study. J Gastrointestin Liver Dis. 2017; 26(3):261-268.10.15403/jgld.2014.1121.263.dal28922438Search in Google Scholar

26. WIESE S, MORTENSEN C, GØTZE JP, et al Cardiac and proinflammatory markers predict prognosis in cirrhosis. Liver Int. 2014; 34(6):e19-30.10.1111/liv.1242824313898Search in Google Scholar

27. KARAGIANNAKIS DS, VLACHOGIANNAKOS J, ANASTASIADIS G, et al. Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia. Dig Dis Sci. 2013; 58(10):3029-3036.10.1007/s10620-013-2693-y23907333Search in Google Scholar

28. LEE W, KU SK, KIM SW, et al. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014; 229(5):620-630.10.1002/jcp.2448524446198Search in Google Scholar

29. BALTA S, MIKHAILIDIS DP, DEMIRKOL S, et al. Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014; 65(9):773-777.10.1177/000331971351349224402320Search in Google Scholar

30. TSCHÖPE C, PAULUS WJ. Doppler echocardiography yields dubious estimates of left ventricular diastolic pressures. Circulation. 2009; 120: 810-820.10.1161/CIRCULATIONAHA.109.86962819720947Search in Google Scholar